Compare ASMB & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | LOCO |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 411.3M |
| IPO Year | 2010 | 2014 |
| Metric | ASMB | LOCO |
|---|---|---|
| Price | $28.45 | $13.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $44.20 | $14.17 |
| AVG Volume (30 Days) | 93.4K | ★ 246.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.78 | 4.65 |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $401,701,000.00 |
| Revenue This Year | N/A | $3.60 |
| Revenue Next Year | $638.39 | $3.98 |
| P/E Ratio | ★ N/A | $15.52 |
| Revenue Growth | N/A | ★ 5.68 |
| 52 Week Low | $10.53 | $8.29 |
| 52 Week High | $39.71 | $14.50 |
| Indicator | ASMB | LOCO |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 57.82 |
| Support Level | $27.10 | $13.42 |
| Resistance Level | $30.58 | $14.50 |
| Average True Range (ATR) | 1.38 | 0.34 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 44.63 | 38.78 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.